中國區營收恢復增長 諾華製藥(NVS.US)Q1業績超預期 上調全年業績指引
格隆匯4月25日丨諾華製藥(NVS.US)第一季度營收129.5億美元,超預期的125.3億美元;其中,中國區營收恢復增長(+1%);淨利潤22.94億美元,超預期的22.7億美元;調整後每股盈餘1.71美元,超預期的1.57美元。公司上調2023年全年營收預期和核心經營利潤預期:現預計營收將增長4-6%,此前為1-5%;預計核心經營利潤將增長7-9%,此前為4-6%;市場預期則為全年業績指引保持不變。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.